Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 23: The PUSH-AHF Study
Author(s): Jozine ter Maaten Added: 7 months ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927). PUSH-AHF (University Medical Center Groningen) aimed to assess the effect of natriuresis-guided therapy in patients with acute heart failure to improve diagnostic response, decongestion and clinical outcomes. 310 patients with a primary diagnosis of… View more

Heart Failure
Author(s): Torbjørn Omland Added: 3 years ago
Acute coronary syndromes (ACS) and heart failure (HF) are both associated with complex neurohormonal activation. Commensurate with advances in pharmacological and device therapies for both conditions, the concept of using circulating biomarkers for diagnosis and risk stratification, as well as for targeting and monitoring therapy, has received great attention. Although many novel biomarkers have… View more

Heart Failure

MI/ACS
Author(s): José Silva Cardoso Added: 3 years ago
Acute heart failure (HF) is a clinical entity characterised by rapid onset of symptoms and signs secondary to abnormal cardiac function, with reduced cardiac output and pulmonary and/or systemic congestion.1 De Novo Acute HF and Acute Decompensation of Chronic HF There are two subtypes of acute heart failure - de novo and acute decompensation of chronic HF.1 In the first, HF is of sudden onset,… View more

Vascular Disease and Surgery

Heart Failure
Author(s): Ali Vazir , Martin R Cowie Added: 3 years ago
Acute heart failure is usually defined as the rapid onset of, or change in, signs and/or symptoms of heart failure resulting in the need for urgent treatment.1 It can occur as the first manifestation of a failing heart (acute de novo heart failure) or it can occur in a patient with a chronic history of heart failure, in which case the term ‘acute decompensation’ is often applied. The acute heart… View more

Heart Failure
Author(s): Ferenc Follath Added: 3 years ago
Q: What are the new treatment options in acute decompensated heart failure? A: The new treatment options are the two recently introduced drugs, the calcium sensitiser, levosimendan which has been introduced in many European countries, and a B-type natriuretic peptide (BNP) Analogon nesiritide, utilised primarily in the US. This BNP causes basal dilation and improves diuresis. Q: How do these… View more

Heart Failure
ACC 22: Results From the EMPULSE Study
Author(s): Mikhail Kosiborod Added: 2 years ago
In this short interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) summarises the main findings of the EMPULSE study, originally presented as a late-breaking trial at ACC.22(NCT04157751). The study investigated the effects of empagliflozin on symptoms,physical limitations and quality of life inacute heart failure. The trial demonstrated that treatment with empagliflozin… View more

Heart Failure
Jozine ter Maaten
Research Area(s) / Expertise:

Heart Failure

 Job title: Cardiologist
Dr Jozine ter Maaten is a cardiologist at the University Medical Center Groningen, specializing in acute heart failure. Her research focuses on understanding congestion and improving diuretic response and outcomes in patients with this condition. Dr ter Maaten completed her PhD on 'Diuretic response and renal biomarkers in heart failure' in 2016 and has since been actively involved in research… View more
Kevin Damman
Research Area(s) / Expertise:

Heart Failure

Imaging & Diagnostics

 Job title: Head of the Heart Transplant and Left Ventricular Device Program
Dr Kevin Damman is Head of the Heart Transplant and Left Ventricular Device Program at the University Medical Center Groningen in the Netherlands. His research interests focus on acute and advanced heart failure, including cardiorenal axis. He is also interested in improving the treatment of acute heart failure patients, with early assessment of decongestive therapies, SGLT2 inhibitors in… View more
Research Area(s) / Expertise: Job title: Professor
Marco Metra is Full Professor of Cardiology and Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, and Editor-in-Chief of theEuropean Journal of Heart Failureand Senior Consulting Editor of theEuropean Heart Journal. Prof Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with heart… View more
AHA 22: Late-Breaker Discussion: The STRONG-HF Trial
Author(s): Alexandre Mebazaa , Harriette Van Spall Added: 1 year ago
AHA 22 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Alexandre Mebazaa (University Hospitals Saint Louis‐Lariboisière, FR), the primary investigator of the anticipated STRONG-HF Trial (NCT03412201). This study aimed to evaluate the safety and efficacy of rapid-optimization heart failuretherapies. 1800 patients were randomized to receive either usual care… View more

Standards & Guidelines

Heart Failure